The company cited Gavi’s failure to procure the 350 million doses it had agreed to buy in May last year for the COVAX facility.
Vaccine maker Novavax Inc said on Tuesday its COVID-19 shot retooled against the Omicron BA.1 variant showed a strong immune response as the fourth dose and met the main goal of strain change in a late-stage study.
Pfizer Inc. on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations.
With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting far fewer will be given each year, pushing the number of shots well below annual flu vaccinations.
The authorization applies for people unable to get updated Omicron-tailored boosters, or those who would choose not to receive any other booster dose.
Novavax Inc. said on Wednesday data from studies in adults and adolescents showed that the booster dose of its COVID vaccine produced robust antibodies against several Omicron variants, including BA.1, BA.2 and BA.5.
Britain’s medicines regulator on Friday approved Novavax’s COVID-19 vaccine for children aged between 12 and 17 years.
The U.S. Centers for Disease Control and Prevention (CDC) on Monday signed off on the use of Novavax Inc.’s COVID-19 vaccine for adolescents aged 12 through 17.
Novavax Inc. said on Monday it had filed for U.S. authorization for use of its COVID-19 vaccine as a booster dose in people who had either received its shots or a different vaccine.
Novavax Inc. on Monday halved its full-year revenue forecast as it does not expect further sales of its COVID-19 shot this year in the United States in the face of a global supply glut and soft demand, sending its shares down 33%.